AI주식인사이트AI Stock Insight
B

명인제약

317450KOSPI

62.9 / 100

Reference Date: 2026-09-08

Financial Score33.5 / 40
News Sentiment15.4 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health and PER is significantly undervalued vs. peers is also solid. Slightly down 3.3% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Myungin Pharmaceutical specializes in developing and producing CNS-focused specialty pharmaceuticals, including treatments for stroke, Parkinson's disease, and depression, securing the top position in the domestic market according to IQVIA 2025 Q4 data. Leveraging its full-process production capabilities from raw material synthesis to finished products, the company expands partnerships with global pharmaceutical firms and maintains a strong market presence in OTC products as well.

Number of Employees

532people

Average Salary

78.7M KRW

Score Calculation Basis

Detailed Financial Score

PER
6.63Industry Average 15.008.0Point

Half of industry avg (excellent)

PBR
0.82Industry Average 1.205.5Point

Lower than industry avg (good)

ROE
12.28Industry Average 8.005.5Point

1.5x industry avg (good)

Debt Ratio
0.14Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 6.5 / 10 points
Revenue Growth Rate
1.5 / 3

Operating Profit Growth Rate
1.5 / 3

ROE Trend
3.5 / 4

Detailed News Sentiment

3 totalPositive 1Neutral 2Negative 0Average Sentiment Score 61.7

Detailed Momentum

52-week position1.0Point

Near 52w low (5%, downtrend)

Current 44,550Won52-week high 121,90052-week low 39,800
1-month return2.0Point

1m -3.26% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0
  • Neutral반기보고서 (2026.06)2026-08-13